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In an era of rapid and changing technological advances, a firm’s survival 
and growth depends on its’ ability to introduce products to the market. Since a 
firm’s growth and survival depends on its’ ability to develop products and 
services over time (Penrose, 1959), the question posed by this study is what 
determines a firm’s ability to introduce products to market?  In this study, a firm’s 
ability to introduce product to markets are influenced by its’ “absorptive capacity” 
to identify and internalize the resource benefits of its’ alliance partners. Such an 
integrated view is absent in firm level and strategic alliance studies of product 
development. A conceptual model of firm product introductions is developed and 
empirically tested. Results generally support the hypotheses of this study.   3 
VALUING STRATEGIC ALLIANCES IN THE BIOTECHNOLOGY INDUSTRY 
 INTRODUCTION 
In an era of rapid and changing technological advances, a firm’s survival 
and growth depends on its’ ability to introduce products to the market (Bettis and 
Hitt, 1995; Deeds and Hills, 1996; Rothaermel 2001 a,b; Rothaermel and Deeds, 
2004; Nerkar and Roberts, 2004; Werther and Kerr, 1995). Since a firm’s growth 
and survival depends on its’ ability to develop products and services over time 
(Penrose, 1959), the question posed by this study is what determines the 
successful launch of a firm’s products? Such a question is of particular 
importance to high technology industries. This is because rapid changes in 
competitive, technological conditions and changing consumer needs require 
firm’s to continually introduce products to meet the changing conditions of the 
market (Bettis and Hitt, 1995). Learning races demand firms to not only bring 
products to markets early (Liebeskind, Oliver, Zucker & Brewer, 1996) but also to 
continually innovate and introduce products to the market. The biotechnology 
industry is reflective of such changing market condition and thus, the question 
posed by this study is particularly relevant to the survival and growth of 
biotechnology firms. As a result, a number of studies have examined the causes 
that determine a firm’s product success (Deeds and Hill, 1996; Nerkar and 
Roberts, 2004; Rothaermel, 2001 a, b; Rothaermel and Deeds, 2004) 
However, research on firm product success tends to mutually exclude firm 
level and inter-firm level causes for firm product success. Firm’s can no longer 
rely on the internal technological and marketing competences in bringing 
products to market but require a greater reliance on strategic partners for the   4 
advancement of their products to market (Teece, 2000). Yet, firm level studies 
emphasize the firm’s technical and marketing competencies (Danneels, 2002; 
Helfat and Peteraf, 2002; Helfat & Raubitschek, 2001; Nerkar and Roberts, 2004; 
Tripsas and Gavetti, 2000) as instrumental to the firm’s product success. 
Specifically, such views are founded on Penrose’s (1959) theory of the firm. 
According to Penrose (1959), a firm is a bundle of productive resources that 
yields a multiplicity of goods and services. Prahalad and Hamels’ (1990) concept 
of “core competence” as well applications of Resource Based View (RBV) 
(Peteraf and Bergen, 2003) emphasize the duality that firm’s internal resources 
and products are two sides of the same coin (Wernerfelt, 1984). Yet, Strategic 
alliances and social network researchers find the cooperation and pooling of 
resources advances the development and marketing of products (Chan, 
Kesinger, Keown & Martin, 1997; Deeds and Hill, 1996; Dyer and Singh, 1998; 
Gulati et al., 2000; Powell et al., 1996; Rothaermel 2001a, b; Rothaermel and 
Deeds, 2004). Hence, according to a strategic network / alliance perspective, a 
firm’s ability to introduce products to markets require combining technologies, 
resources and commercializing experiences that no one company possesses 
(Teece, 2000). That is, research breakthroughs are broadly distributed so that no 
single firm has all the internal capabilities necessary for product market success 
(Powell, Koput, and Smith-Doerr 1996). In particular, biotechnology firms are 
compelled to rely on strategic alliances for support in the various phases of the 
product and market development process (Teece, 2000).  For instance, the 
studies of Deeds and Hill (1996), Rothaermel (2001a, b) and Rothaermel and   5 
Deeds (2004) show the number of new product introductions are affected by its 
strategic alliances.  
As high technology industries tend to be driven by heightened reliance on 
knowledge as a sources of competitive gain (Bettis and Hitt, 1995), a firm’s 
internal knowledge and resource and its’ ability to access external knowledge 
and resources jointly impact a firm’s ability to bring products to the market. In 
particular, a firm’s knowledge and learning –as a resource- has been advanced 
by Cohen and Levinthals’ (1990) concept of “absorptive capacity” (Cohen and 
Levinthal, 1990). According to Cohen and Levinthal (1990), a firm’s prior 
knowledge experience positively influences its ability to absorb external 
information and resources. Hence, given the increasing attention to the 
knowledge dimension of a firm’s resources and the increasing reliance of firm’s 
on strategic alliances, a firm’s absorptive capacity impacts its ability integrate 
alliance expertise and thus impact a firm’s product success. Namely, this study 
argues a firm’s ability to introduce products to market is constrained by a firm’s 
absorptive capacity in gaining access to resources of its’ strategic alliance 
partners. In Harrison, Hitt, Hoskisson & Irelands’ (2001) study of strategic 
alliances, they contend strategic alliance failure is largely attributed to failures of 
management to not only correctly identify the gains afforded from complementary 
partners but also the ability to exploit such gains. In this study, we argue a firm’s 
product performance is influenced by its’ absorptive capacity to identify and 
internalize the resource benefits of its’ alliance partners. Such an integrated view 
is absent in either of the firm and inter-firm levels focus of prior studies.    6 
This approach is examined in the biotechnology industry for two reasons. 
First, the biotechnology industry has and continues to experience continual and 
rapid technological changes and therefore examining the causes that determine 
a firm ability to introduce product to markets is particularly important to the 
survival and growth of this industry. Second, prior studies has examined in albeit 
separate developments absorptive capacity (Lane and Lubatkin, 1998; Mowery, 
Oxley & Silverman, 1996; Nerkar and Roberts, 2004) and strategic alliances 
(Chan et al., 1997; Deeds and Hill, 1996; Dyer and Singh, 1998; Gulati, Nohria, & 
Zaheer, 2000; Powell et al., 1996; Rothaermel 2001a, b; Rothaermel and Deeds, 
2004) arguments in this industry. Since a firm’s ability to introduce product and 
services are highly dependent on a firm’s internal R&D develop experiences and 
its’ strategic alliances, the integration of absorptive capacity and strategic 
alliances arguments appears particularly relevant for this industry.  
To organize this study, the first section provides a background of the 
biotechnology industry and reviews the literature on strategic alliances and 
absorptive capacity. Hypotheses are derived that incorporate arguments from 
these different levels of analysis as causal factors impacting a firm’s ability to 
introduce products to the biotechnology market. The second section is a 
discussion of our data and methods. A sample of 209 biotechnology firms in the 
2004 was collected. Based on this sample, Weighted Least Squares estimations 
were conducted. Lastly, the conclusions and contributions of this study are 
discussed. 
CONCEPTUAL MODEL 
Industry Background   7 
Although there is no formal definition of biotechnology, an agreed upon 
definition is “processes that seek to preserve or transform biological materials of 
animal, vegetable, microbial or viral origin into products of commercial, 
economic, social and/or hygienic utility and value’’(Hulse 2004). This definition 
includes biotechnology firms, such as Amgen, Biogen and Genentech, Pfizer, 
Monsanto, Dow Agrosciences etc. The growth of biotechnology related products 
and services had been advanced by basic biotechnology research in genetic 
engineering, genome mapping, recombinatory chemistry. Since 1992, U.S. 
biotechnology related produce and service related revenues increased from $8 
billion in 1992 to $39.2 billion in 2003.  As the study’s focus in understanding the 
determinants that impact a firm’s ability to bring products to market, a firm’s 
product-market performance is our dependent variable of interest and is defined 
as the cumulative number of commercialized products that have received 
regulatory approval. Similar definitions of firm performance have also been used 
by prior studies (Deeds and Hill, 1996; Rothaermel 2001a,b; Rothaermel and 
Deeds, 2004; Nerkar and Roberts, 2004) 
Through out the inception of the biotechnology industry, the population of 
U.S biotechnology companies has grown to 1,473 firms by 2004 (Biotechnology 
Industry Organization). This explosive growth of biotechnology companies in the 
United States has bred highly competitive conditions that have induced a “winner 
takes all” technology race for industry profits ((Liebeskind et al., 1996). As a 
result, a firm’s competitive survival rests on the firm’s ability to rapidly develop 
new products and bring them to market so as to gain early cash flows for greater 
financial independence, external visibility and legitimacy, and early market share   8 
(Deeds and Hill, 1996; Schoonhoven, Eisenhardt, and Lyman 1990).  Along with 
a highly competitive market, the development of biotechnology products and 
service is an expensive, time consuming and risky endeavor.  Drug development 
timelines average 7 to 11 years from discovery to launch and Research and 
commercializing investments range from $100 to 300 million per product) (Powell 
et al., 1996).  FDA regulatory approval and market approval have also raised the 
uncertainty in the success of product launches (Deeds and Hill, 1996; Pisano, 
1990)  
These highly competitive conditions have compelled biotechnology firms 
to form strategic alliance to commercialize basic biotechnological research 
(Deeds and Hill, 1996; Teece, 2000). As result, since the inception of the 
biotechnology industry, strategic alliances have grown significantly (Chan et al., 
1997; Powell et al., 1996). A strategic alliance is as: 
“…as any voluntarily initiated cooperative agreement between firms that 
involves exchange, sharing, or co-development, and it can include 
contributions by partners of capital, technology, or firm specific assets” 
(Rowley, Behrens, & Krackhardt, 2000, p.370). 
Strategic Alliance  
Various arguments have been used to explain the relationship of strategic 
alliances to firm’s product performance. Strategic alliances can be leveraged into 
dominant market share positions that translate into learning curve advantages to 
advance future product developments (Deeds and Hill 1996; Stalk and Hout, 
1990; Schoonhoven et al., 1990). In addition, strategic alliances can increase a 
firm’s ability to bring products to market through increased flexibility to changing   9 
technology conditions, access to external and complementary commercializing 
assets (Deeds and Hill, 1996; Harrison et al., 2001; Pennings and Harianto, 
1992), access to foreign markets, and development new distribution channels 
(Deeds and Hill, 1996; Harrison et al., 2001; Koza and Lewin, 1998; Parkhe, 
1991; Rothaermel and Deeds, 2004). Of particular import to the biotechnology 
industry is strategic alliances provide access to complementary research 
expertises and provides access to commercializing assets, such as downstream 
marketing, production and distribution assets (Deeds and Hill, 1996; Rothaermel 
and Deeds, 2004; Teece, 2000). In discussing a firm’s product performance, 
Schumpeter’s (1934) distinction of “invention” and “innovation” is worthy of 
mention. According to Schumpeter (1934), invention occurs through the novel 
recombination of knowledge experiences, while invention occurs when an 
innovation has a marketable use (Nerkar and Roberts, 2004). Through strategic 
alliances, the pooling of complementary research expertises among Research 
start-ups and access to downstream pharmaceutical firms’ commercialization 
assets serve to transform biotechnology inventions (i.e. genetic engineering, 
genome mapping, recombinatory chemistry, etc) of start-up operations into 
commercializable product innovations (i.e. therapeutic products). Hence, 
strategic alliances are positively related to a firm product performance.  
However, increasing the number of strategic alliances could eventually 
exhibit diminishing firm product performance. In drawing on Deeds and Hill 
(1996), they argue the relationships between the number of firm strategic 
alliances and the number of products marketed exhibits a non-monotonic or 
inverted U shape relationship. They reason, as the individual firm increases its   10 
number of alliances, it is “likely to enter some alliances whose marginal 
contribution is relatively minor.”(p.44)  Deeds and Hill (1996) continue that 
“selection and management of alliance partners is likely to be negatively related 
to the number of alliances the firm is managing.”  They attribute this to the 
managers’ bounded rationality to select and monitor alliance partner behaviors. 
The second reason for the “inverted U” shape takes into account contractual 
problems involved in forming alliances. Strategic alliances are subject to threats 
from adverse selection, moral hazard and hold up (Barney, 2002). Such alliance 
threats are particularly problematic in the presence of co-asset specificity among 
partnering firms (Jones et al, 1997; Osborn & Hagedoorn, 1997; Pisano, 1990).  
In particular, increases in firm alliances, increases the chances for firms to align 
with firms that have a poor match of assets, do not hold up to their end of the 
deal, and or can exhibit opportunistic behavior in exploiting the agreement terms 
Jones et al., 1997; Osborn & Hagedoorn, 1997;. Pisano, 1990). Although these 
arguments draw on Transaction cost considerations, this consistent with the 
diminishing effects found by Deeds and Hill (1996).  
Strategic alliances can be leveraged into dominant market share positions 
that translate into learning curve advantages to advance future product 
developments (Deeds and Hill 1996; Stalk and Hout 1990; Schoonhoven et al., 
1990). Strategic alliances also increases a firm’s ability to bring products to 
market through increased flexibility to changing technology conditions, access to 
external and complementary commercializing assets (Deeds and Hill, 1996; Koza 
and Lewin, 1998; Harrison et al., 2001; Pennings and Harianto, 1992), and 
access to foreign markets, and developing new distribution channels (Deeds and   11 
Hill, 1996; Harrison et al., 2001; Koza and Lewin, 1998; Parkhe, 1991; 
Rothaermel and Deeds, 2004). Of particular import to the biotechnology industry 
is: strategic alliances provide access to complementary and commercializing 
assets (Deeds and Hill, 1996; Rothaermel and Deeds, 2004; Teece, 2000). As 
Deeds and Hill (1996), note “strategic alliances are an effective way of quickly 
assembling the required set of complementary assets”. Hill and Jones (1995) 
also note strategic alliances allow the sharing of risks and costs involved in 
product development and thus should positively increase the number of product 
market launches.  As a result, consistent with a general premise of social 
network research, strategic alliances should positive impact an organizational 
performance in regards to the number of products markets. This is because the 
greater the number of alliances, the greater the ability for a firm to be responsive 
to new technologies and provide access external yet complementary assets. All 
of which facilitate the creating of new products as well as provide access to 
downstream marketing, distribution and production assets in bringing such new 
products to market (Deeds and Hill, 1996; Rothaermel and Deeds, 2004). Deed 
and Hills proposes and finds support for a linear relationship between a firm’s 
product performance and strategic alliances. 
However, increasing the number of strategic alliances yield diminishing 
effects on firm’s product performance. As an alternate hypothesis, Deeds and Hill 
(1996) find a firm’s product performance has a non-monotonic or inverted U 
shape relationship to the number of a firm’s strategic alliances. They reason, as 
the individual firm increases its number of alliances, it is “likely to enter some 
alliances whose marginal contribution is relatively minor.” (pg. 44) Second, they   12 
attribute the diminishing effects to the managers’ bounded rationality in selecting 
and governing effective alliance behaviors.  Contractual problems grow with 
increasing alliances. Strategic alliances are subject to threats from adverse 
selection, moral hazard and hold up (Barney, 2001). Such alliance threats are 
particularly problematic in the presence of co-asset specificity among partnering 
firms (Jones et al., 1997; Pisano, 1990).  In particular, as the firm enters into 
more and more alliances, its chances of making alliances with firms that have a 
poor match of assets, do not hold up to their end of the deal, and or can exhibit 
opportunistic behavior in exploiting the agreement with the other firm increases 
(Deeds and Hill, 1996; Jones et al., 1997). Third, bounded rationality places limits 
on the firm’s ability to learn the experiences and knowledge from their alliance 
partners and thus result in diminishing effects to a firm product performance. The 
following is hypothesized: 
H1: a firm’s product market performance –number of products on the 
market- has an “inverted, U-shaped relationship” to the total number of its’ 
strategic alliances. 
Since strategic alliances can take a variety of exchange relationships –
such as licensing, manufacturing, research and development, equity and non-
equity forms of agreements (see Deeds and Hill, 1996; Harrison et al., 2001; 
Koza and Lewin, 1998; Lane and Lubatkin, 1998; Pennings and Harianto, 1992; 
Rothaermel and Deeds, 2004), different types of alliances should have different 
impacts on a firm’s product performance. As the pooling of research and 
commercializing assets are requisites to the   transformation of a firm’s   13 
inventions into an innovation, Schumpeter’s (1934) invention and innovation 
distinction are examined with the following hypotheses,  
H2:  A firm’s R&D and Marketing alliances have the greatest positive 
effect on a firm’s product performance.  
As a firm’s technological expertise and market experiences often develop in 
tandem (Danneels, 2002; Nerkar and Roberts, 2004) and since research and 
development and marketing alliances mutually complement the 
commercialization of basic research (Nerkar and Roberts, 2004;Teece, 2000), an 
addendum to hypothesis 2 is proposed  
H2a: A firm’s product performance is positively related to the joint 
influence of a firm’s R&D and marketing alliances. 
Absorptive Capacity 
In addition to strategic alliance arguments, a firm’s absorptive capacity 
also impacts firm product performance. Forwarded by Cohen and Levinthal 
(1990), the concept of “absorptive capacity” refers) refers to the firm’s “ability to 
recognize the value of new information, assimilate it, and apply it to commercial 
ends” (Cohen and Levinthal, 1990, p. 128).  A firm’s absorptive capacity to 
assimilate new information is directly a function of the firm’s prior knowledge and, 
therefore, absorptive capacity tends to develop in a cumulative or path 
dependent manner (Bosch, Volberda, & Boer, 1999; Cohen & Levinthal, 1990; 
Lane & Lubatkin, 1998; Pennings and Harianto, 1992).  Cohen and Levinthal 
(1990) further add that a firm’s absorptive capability in assimilating  
“… information is a function of the richness of pre-existing knowledge 
structure: learning is cumulative and learning performance is greatest   14 
when the object of learning is related to what is already known” 
(1990:131). 
Nerkar and Roberts (2004) find a firm’s prior technological and product-
marketing experiences jointly impact a firm’s “combinative” ability in developing 
and introducing pharmaceutical products to the market. Namely, Nerkar and 
Roberts (2004) argue a firm’s ability to relate its’ technological and product-
market experience to other “promixal” and distant” experiences positively impacts 
a firm’s ability to launch products on to the market. In Danneels (1999) study of 
the apparel industry, a firm’s marketing experiences shapes its ability to 
introduce new product lines. In Pennings and Hariantos’ (1992) study of the U.S. 
banking system, a firm’s prior technological experiences impacts its ability to 
launch new information technology services. As firm’s age has been used as a 
proxy for a firm’s prior experience (Pennings and Harianto, 1992), the following 
firm level hypothesized is proposed:  
H3: A firm’s accumulated experiences is positively related to its’ product 
performance.  
However such firm level investigations of absorptive capacity omit inter-
firm transfers of knowledge. In drawing on Cohen and Levinthals’ (1990) notion 
of “absorptive capacity”, Lane and Lubatkin (1998) examine the transfer of 
knowledge among strategic alliance partners in the biotechnology industry.  In 
citing Nicholls-Nixon, Lane and Lubatkin (1998) cautions: 
“the findings from this study [Nicolls-Nixon, 1993:191) suggest that it is a 
dangerous to regard strategic alliances as a panacea for staying in touch 
with rapidly changing technological environments. This is because the   15 
benefits associated with the use of strategic alliances are not automatic. 
Conscious management action is required…to ensure that externally 
sourced technology can be acquired and integrated into the firm’s 
technological capabilities’ (Nicholls-Nixon, 1993:191)” (463) 
Namely, in order for a firm to understand and commercialize the value of external 
knowledge, a firm needs to meet two criteria (Lane and Lubatkin, 1998). First, a 
firm is required to have a basic and prior understanding to the new and external 
knowledge (Cohen and Levinthal, 1990; Lane and Lubatkin, 1998). Basic 
knowledge consists of the “general understanding of the traditions and 
techniques upon which a discipline is based” (Lane and Lubatkin, 1998, pg. 464). 
For instance, a chemist will not appreciate advances in biotechnology with out 
first having a basic understanding of the biological sciences (Lane and Lubatkin, 
1998). For instance, in Monsanto’s entrance into the biotechnology industry, it 
first developed in house biotechnology research capabilities before undertaking 
integration of external biotechnologies (Leonard-Barton, Dorothy & Pisano, 
1993). As a result, in order for a firm to value the resources and technologies of 
its alliance partner, “it must possess some amount of prior knowledge basic to 
the new knowledge” (Lane and Lubatkin, 1998, pg 464). Hence, even though 
strategic alliances can provide access to valuable and complementary resources, 
firms can fail to take advantage of alliance gains because their prior knowledge is 
insufficient in determining their value. As a result, a firm with greater experience 
is better able to learn from their past experiences and can draw on past 
experiences to make inferences on the value of partnering firms. For instance, 
firms with greater experience and thus absorptive capacity benefit from learning   16 
curve effects (Zahra and George, 2002). This includes not only improvements in 
operational efficiencies (Levinthal and March, 1993; Pennings and Harianto, 
1992) but past experiences constrains a firm’s search to information that is close 
or proximally related to the firm’s experiences (Zahra and George, 2002). As a 
result, firms with greater experiences will tend to form alliances that build upon 
the firm’s existing knowledge base. A firm’s absorptive capacity leverages the 
resources of its’ alliance partners by identifying complementary
2 yet similar 
partners (Lane and Lubatkin, 1998; Pennings and Harianto, 1992; Nerkar and 
Roberts, 2004; Zahra and George, 2002) who can advance products that builds 
upon the firm’s core experiences. As a result, a firm’s prior experiences can be 
used to not only select better fit partners but can use their prior experience to 
integrate the resources of partnering firms in ways that advance its core 
experiences. As a result, this increases the firm’s ability to introduce products to 
the market. Such an absorptive capacity argument is absent in prior strategic 
alliance studies. Hence, the following is hypothesized: 
H3a : A firm’s accumulated experience has a positive moderating effect on 
the firm’s strategic alliances. 
A second criterion is: the transfer and understanding of knowledge among 
alliance increases with the diversity of prior knowledge experiences held by 
aligning partiers (Cohen and Levinthal, 1990; Lane and Lubatkin, 1998; Nerkar 
and Roberts, 2004; Zahra and George, 2002). In that, firms with diverse research 
and marketing experience are more likely to understand the value of the 
                                                 
2 Zahra and George (2002) notes “Lofstrom (2000) reports that knowledge complementarity, defined as the 
extent to which knowledge is related to and at the same time different from the knowledge of contacts in 
their information networks” (p. 193)   17 
resources and information of alliance partners. This is because the diversity in a 
firm's prior knowledge has been suggested to strengthen the assimilation of 
external information and development of new innovations (Bosch et al, 1999; 
Cohen & Levinthal, 1990; Nerkar and Roberts, 2004; Zahra & George, 2002). As 
Cohen and Levinthal (1990) note,  
"a diverse background [knowledge] provides a more robust basis for 
learning because it increases the prospect that incoming information will 
relate to what is known.' (Cohen and Levinthal, 1990,131).  
Further, Bosch et al (1999) also argue firms with broader knowledge experiences 
- knowledge scope- are more able to explore and assimilate diverse knowledge 
sources. In addition in drawing on Nicholls-Nixon (1993), Lane and Lubatkin 
(1998) comment,  
“She found that firms with high levels of absorptive capacity invest more in 
their own R&D, utilized alliance, had more in house expertise with relevant 
technologies, and managed communications with alliance partners more 
effectively” (pg 463) 
This is, however, distinct from argument raised in hypothesis 3a. A firm’s 
absorptive capacity is a multi-dimensional construct (see Zahra and George, 
2002; Nerkar and Roberts, 2004) that yield different advantages to a firm’s ability 
to absorb external information. In particular, a firm with a diversity of prior 
knowledge experiences –as opposed to cumulative experiences- can draw on its’ 
broader base of experiences to make inferences of new technologies and 
resources held by its’ alliance partners (Nerkar and Roberts, 2004; Pennings and 
Harianto, 1992). Such diversity of prior knowledge is similarly described by   18 
Nerkar and Roberts’ (2004) notion of a firm’s proximal and distal experiences. In 
that, the greater the diversity of firms’ prior knowledge experiences, the greater 
the degree to which firms share proximally similar experiences. For instance, 
firms involved in different research programs such as cancer therapies, protein 
engineering, medical diagnostics, screening for molecular compounds etc are 
more likely to understand and recombine the technologies and resources held by 
their aligning partners, than those firms with more specialized research 
programs. Although a firm’s cumulative experiences are correlated with its prior 
knowledge diversity, the distinction is: knowledge diversity increase the degree to 
which a firm’s experiences can relate to external sources.  A firm’s knowledge 
diversity broadens its’ search and thus exposes the firm to greater diversity of 
alliance resources. This allows for a greater exchange and recombination of 
partner resources to bring about the development of new research. Since 
Schumpeterian innovation (1934) is a process of novel recombination of 
knowledge experiences, a firm’s diversity of prior knowledge experiences 
enables a greater absorption of varied alliance resources and thus should 
positively impact a firm’s product performance
3. This is consistent with Ng’s 
(2003) study of strategic change, where a firm’s internal knowledge diversity 
increases the firm’s ability to relate to varied external information sources. As a 
result, a firm’s prior knowledge diversity should, thus, promote the absorption of 
the knowledge and expertise of its’ alliance partners and in turn increase the 
firm’s product performance. The following is hypothesized: 
                                                 
3As Lane and Lubatkin (1998) notes transfers of knowledge among aligning partners are a one-way form of 
communicative learning, however, they contend ‘the factors that influence one-way learning also effect 
two-way learning’(p. 464).   19 
H4: A firm’s prior knowledge diversity is positively related to its’ product 
performance. 
H4a : A firm’s prior knowledge diversity has a positive moderating effect 
on the firm’s strategic alliances. 
More over, since the biotechnology industry has experienced significant 
mergers and acquisition activities (Thayer, 2001), the cumulative experiences 
gained from a firm’s merger and acquisitions should impact it’s prior knowledge 
and thus absorptive capacity. In particular, mergers and acquisition can involve 
changes in firm’s boundary of operations into different product markets. For 
example, Monsanto was formerly a chemical company and through the 
acquisition of Searle –a pharmaceutical company, Monsanto had acquired 
research expertise in the pharmaceutical domain (see Leonard-Barton et al., 
1993). As a result, a firm’s mergers and acquisition can increase or decrease (i.e.  
Divestitures) the diversity of knowledge base through such merger and 
acquisition activities. Hence, from an absorptive capacity perspective, mergers 
and acquisitions involve not only the control and ownership of another firm’s 
physical assets, but it also provides direct access to the merged and acquired 
firm’s knowledge and experiences. This can broaden a firm’s prior knowledge 
and thus absorptive capacity. Increases in a firm’s absorptive capacity increase 
the firm’s ability to integrate the resources of its alliance partners in advancing a 
firm’s product performance. The following addendum to hypothesis 4 is provided.  
H4b: A firm’s history of mergers and acquisitions has positive effect on a 
firm’s product performance.   20 
H4c : A firm’s history of mergers and acquisition has a positive moderating 




Data from public biotechnology, pharmaceutical, and related agricultural 
companies was examined from a BioScan Database (April, 2004). BioScan 
(2004) (American Health Consultants, 2003) is one of the most comprehensive 
databases on strategic alliances in the biotechnology industry. BioScan has been 
used by network researchers to examine strategic alliances in the biotechnology 
industry (Deeds and Hill, 1996; Lane and Lubatkin, 1998; Powell et al., 1996; 
Rothaermel, 2001 a,b; Rothaermel and Deeds, 2004). Consistent with prior cross 
sectional studies (Deed and Hill, 1996; Rothaermel, 2001a,b; Rothaermel and 
Deeds, 2004), a cross sectional analysis is conducted such that comparisons can 
be made to these earlier studies. As a biotechnology firm can be involved in an 
array of agricultural and pharmaceutical related products and services, 
biotechnology is used as an over-arching term that encompasses such products. 
Data Sample  
  From the BioScan database (2004), an initial sample of 559 public 
biotechnology firms was available for econometric analysis.  This sample 
includes biotechnology firms producing pharmaceutical and agricultural related 
products and services. Table 1 shows the distribution of firms among 6 product 
categories. 
[Insert Table 1 here]   21 
Products in the agricultural category were from firms producing only 
agricultural related products (e.g. fertilizer, chemicals, genetically modified seed, 
animal medicine, and livestock genetics). Biotechnology includes products and 
services such as production of monoclonal and polyclonal antibodies, diagnostic 
services -DNA sequencing, analysis of gene functions, biological software 
(bioinformatics), and or research equipment. Products designed for human health 
or use, for example human therapeutics, is defined as pharmaceutical. For 
example: insulin for the treatment of diabetes and growth hormones for the 
treatment of growth hormone deficiencies. Since the majority of the 
biotechnology firms consist largely of pharmaceutical products followed by 
biotechnology and the combination thereof, the analysis is conducted on a 
sample of these firms. Our sample of biotechnology firms are, therefore, inclusive 
of firms that produce and market biotechnology and pharmaceutical products. 
Such a sample is adopted because it also allows for comparison to Deeds and 
Hill (1996) and Rothaermel and Deeds (2004). 
  As the dependent variable of interest is a firm’s product performance, the 
number of a firm’s products that has completed all phases of product 
development –preclinical, phase I, phase II and phase III, received FDA 
approval- and are currently being marketed are recorded (see also Deeds and 
Hill, 1996; Rothaermel and Deeds, 2004). Biotechnology firms with no products 
are removed. In addition, outlying firms with extremely large numbers of 
marketed products were eliminated from the sample. For example, one firm had 
reported 8,800 products and fell outside the range of product numbers for the 
rest of the dataset. More over, firms with an IPO at the time of this data collection   22 
2004 and firms with no employees were removed. The final data set used for 
econometric analyses contained 241 firm observations for the year 2004 
(N=241). 
Measures 
Dependent variable: A biotechnology firm’s products, (PMR), is a count of each 
firm’s product that has successfully completed all stages of the product 
development process –preclinical, phase I, phase II and phase III, received FDA 
approval- and are now being commercialized. This measure was also used by 
Deeds and Hill (1996) and Rothaermel and Deeds (2004). Their product market 
variable was on an earlier BioScan data base (1991).  
Independent variables:  Strategic alliances: A biotechnology firm’s strategic 
alliances, A, is a count variable of the cumulative alliances formed by the firm, 
since its founding. This strategic alliance variable, A, consists of the aggregation 
of non-equity alliances. This includes Licensing, (LI), Research and Development 
(RD), Marketing, (MK), Manufacturing, (MN) and Distribution, (DI) agreements. 
These forms of non-equity alliances are commonly found in strategic alliance 
studies in high technology industries (Chan et al., 1997; Deeds and Hill, 1996; 
Lane and Lubatkin, 1998; Powell et al., 1996; Rothaermel and Deeds, 2004). To 
test for the non-monotonic influences of strategic alliances, the quadratic form of 
this strategic alliance variable, A
2, is included.  
Absorptive capacity: Absorptive capacity is a multi-dimensional construct and 
thus a variety of measures have been used in absorptive capacity research 
(Lane and Lubatkin, 1998; Nerkar and Roberts, 2004; see Zahra and George, 
2002 for a review of measures).  Measures of the absorptive capacity construct   23 
have been based on a firm’s accumulated experiences (Zahra and George 
2002). Hence based on a firm’s accumulated experiences, three measures of 
absorptive capacity are introduced. This enables one to capture the multi-
dimensional dimensions of absorptive capacity. First, a firm’s age, (G) is used as 
a proxy for a firm’s absorptive capacity. This measure follows from Pennings and 
Harianto (1992)
4. Second, to capture the diverse element of the absorptive 
capacity construct, a firm’s knowledge diversity is measured by the research 
diversity variable, (DIV). Research diversity is a count of the firm’s number of 
distinct areas of research development, (DIV). A firm’s research diversity, (DIV), 
is a count of distinct technological and/or research areas of specialization. This 
diversity measure reflects the number of subfields in which the firm has 
participated in. BioScan (2004) provides a description of the distinct areas of 
research application and focus pursued by each company
5. This diversity 
                                                 
4Cohen and Levinthal (1990) and Lane and Lubatkin (1998) have used the ratio of R&D expenditures to 
sales. 
5 As an example of a representative firm in the BioScan database: “Cancer diagnostics and therapeutics: 
oncogenes, including c-abl oncogene in chronic myelogenous leukemia, transforming growth factor beta 3 
(TGF-B3), tumor inhibitory factor (TIF), DNA probes, more than 200 MAbs, oncogenes, tumor suppressor 
genes, AIDS diagnostic, TGF-alpha MAb-based diagnostic, A representative biotechnology firm would 
involve in the following research development activities: “in vivo radioisotopic MAb-based diagnostics for 
neu, P53, EGF-R, EGF, TGF, and GCSF 
 
Therapeutics: tyrosine-specific protein kinase inhibitors, tumor growth inhibitors (TGIs) 
 
Automated screening systems for chemicals that modulate gene expression of specific targets in various 
disease areas 
 
Automated oncogene-based drug screens for inflammation, anemia, and other human therapeutics 
 
TGF-beta 3 for wound healing 
 
Chromosomal translocation technology 
 
Drugs to specifically inhibit functional activities associated with oncogene-encoded proteins 
 
Application of technology for the development of pharmaceuticals outside the field of cancer 
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measure has been used by (Rothaermel and Deeds, 2004; Shan, Walker & 
Kogut, 1994). This diversity measure is correlated with the number of products in 
development (Rothaermel and Deeds, 2004). Nicholls-Nixon (1993) uses the 
number of products in research development as a measure of absorptive 
capacity. Hence to capture the diverse element of absorptive capacity, the 
research diversity measure also includes number of products in development. 
Third, as absorptive capacity is subject to path dependent processes (Zahra and 
George, 2002), a firm’s history of acquisitions and mergers is used to capture the 
diversity of firm experiences that occur from the acquisition or loss of knowledge 
through changes in a firm’s boundary of operations. Mergers and acquisitions 
involve not only the control and ownership of another firm’s physical assets, but it 
also provides direct access to the merged and acquired firm’s knowledge and 
experiences. Since the biotechnology industry had experienced significant 
mergers and acquisitions (Thayer, 2001), the cumulative experiences gained 
from a firm’s merger and acquisition history is used as another diversity measure 
of a firm’s absorptive capacity. It is computed as the difference in the cumulative 
number of firm mergers less divestitures, (NETM). This count variable, however, 
does assume merger and divestiture activities are equally weighted.  
Control Variables: In order to distinguish scale efficiency effects from absorptive 
capacity influences, estimated models are controlled for firm size. In knowledge 
intensive industries, size is measured by the number of employees (Rothaermel 
and Deeds, 2004; Shan et al., 1994). As a result, firm size is measured by the 
number of firm employees, (E). In addition, the location of the firm is coded as a 
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dummy variable (0= U.S. based, 1 non-US based) to account for institutional 
differences (Rothaermel and Deeds, 2004). The number of subsidiaries held by a 
firm is included because they provide access to either foreign markets and or 
provide entrance into new product-markets. Lastly, the number of institutional 
investors (i.e. investors from major banks, fund agencies) is also included. 
Investors provide sources of funding necessary to bringing products to markets. 
Since significant investments are tied up in R&D commitments, such external 
investors should positively impact the number of products on the market.  
Estimation Procedure 
To test hypotheses 1-4, Nested Hierarchical Weighted Least Squares 
(WLS) method is applied to six econometric models shown in table 4.  Models 1-
6 were estimated with the Shazam econometrics software (version 9.0). In 
estimating these models, tests for heteroscedacity, multicollinearity, as their 
presence can lead to problems of statistical inference and OLS estimates that 
are not BLUE (Greene, 2000; Wooldridge, 2003). Heteroscedastic (ARCH test) 
indicate the presence of significant heteroscedacity in all models. To correct for 
heteroscedacity, the estimated parameters in all models were weighted by the 
squared values of the size variable, employees, (E). As firm size exhibits very 
significant variation (see table 1: descriptive statistics), it is a significant source of 
heteroscedacity. Heteroscedacity tests are then re-tested on this WLS linear 
model and ARCH tests were not significant at the 90% significance. Low 
correlations among variables were observed (also shown in table 2) and 
multicollinearity does not appear to be a problem (Greene, 2000; Wooldridge, 
2003).    26 
RESULTS 
The descriptive statistics for the theoretical variables of interests and their 
correlations are shown in tables 2 and 3. The WLS regression results for models 
1-6 are shown in table 4. Standardized coefficient estimates are reported. 
[INSERT TABLES 2, 3, & 4, HERE] 
  In model 1, all control variables were not significant. However, in model 2, 
a firm’s subsidiaries (S) variable is positive and significant. This is consistent with 
Rothaermel and Deeds (2004).  The alliance variables, A and A
2, are also 
significant and show an inverted U shape relationship to the firm’s product 
performance (PMR). This was also evident in all remaining models, this supports 
hypothesis 1. Prior studies, Deeds and Hill (1996) have also found empirical 
support for this relationship. However, unlike Deeds and Hill (1996), this study’s 
data was collected at a much later stage of industry maturity. Hence, this study 
reinforces the findings of Deeds and Hill (1996) and goes on to further suggest 
that this inverted U shaped relationship is robust to different stages of industry 
development. This performance relationship may reflect an intrinsic structural 
feature of alliance relationships. In model 2a, the partial effects of each strategic 
alliance agreement was estimated.  Licensing (LI), Marketing (MK) and 
Distribution (DI) were significant and positive. However Research and 
Development (RD) was not significant, but later significant in model 2b. In model 
2b, the interactions between a firm’s R&D (RD) and marketing (MK) are 
estimated. In model 2b, Research and Development (RD) and Marketing (MK) 
are significant and positive and yield the greatest impact to a firm’s product 
performance, relative to other alliances. This supports hypothesis 2. However,   27 
the interaction between these variables is significant but negative. Hypothesis 2a 
is not supported. This finding is contrary to prior research findings where 
research expertise and marketing competence mutually complement the 
advancement of a firm’s products to market (Danneels, 2002; Nerkar and 
Roberts, 2004). Model 2b results may suggest marketing and research and 
development alliances may be viewed as competing trade offs, especially given 
the finite and limited financial resources of firms. 
In model 3, the inverted U shape relationship is still maintained, however, 
a firm’s age, (G), was not significant. Hypothesis 3 is thus not supported in this 
model. However, in model 4, when the interactions between a firm’s age, G, and 
the number of alliances, A, was included, a firm’s age, G, was positive and 
significant. Rothaermel and Deeds (2004) also finds similar support for firm age. 
Thus, like Rothaermel and Deeds (2004), hypothesis 3 is supported in model 4. 
In addition, the interaction between age and alliances was significant and 
positive. Although Rothaermel and Deeds (2004) finds positive interactions 
between a firm’s age and exploration alliances, our results are similar. Model 4 
shows comparable results of a positive interaction between the total firm 
alliances, A and a firm’s age, G.  This supports the argument that a firm’s 
absorptive capacity –cumulative experiences- can be used to value and leverage 
the resources of its’ alliance partners in ways that builds upon the firm’s core 
experiences. As a result, this increases the firm’s ability to introduce products to 
the market. Stated differently, this result suggests a firm’s experience positively 
impacts its ability to leverage its’ past experiences to absorb the resources of its   28 
alliance partners. In doing so, this increases the firm’s product performance. 
Hypothesis 3a is supported.  
In model 5, the diverse aspect of a firm’s absorptive capacity is estimated 
by the research diversity variable, (DIV). This coefficient is positive and 
significant. This supports hypothesis 4. In model 5a, the interaction between a 
firm’s diversity and alliance is significant and positive at p=11.2%). Hypothesis 4a 
is supported. This is consistent with Cohen and Levinthal (1990) and Lane and 
Lubatkin (1998) arguments that a firm’s ability to relate to external information is 
dependent on the diversity of the firm’s prior knowledge and expertise. Our 
results are also consistent with Nerkar and Roberts (2004) who found that a 
firm’s “proximal distant” – or diversity- positively assists its ability to gain access 
to complementary assets and advance a firm’s products to market. However, this 
study further adds: the coefficient on the squared interaction of these terms was 
also found to be negative and significant. Thus, a firm’s absorptive capacity to 
internalize external information sources is subject to diminishing effects. 
Research in absorptive capacity tends to focus on the mechanisms that explain 
for the absorption of external information (i.e., combinatorial routines, 
organizational search, learning, etc) (Zahra and George, 2002). These results 
suggest there may be limits imposed on these absorptive mechanisms. Lastly, in 
model 6, a firm’s Net mergers, (NETM), is significant and positive. This supports 
hypothesis 4b. Similar to earlier results, model 6a shows the interaction 
estimates of a firm’s net mergers, (NETM) and alliances. The interactions are 
significant and exhibit a non-monotonic or diminishing curve effect. This supports 
hypothesis 4b. Hence, although a firm’s net mergers has a positive moderating   29 
effect on the firm’s strategic alliances in bringing a firm’s product to the market, 
this effect is subject to diminishing returns.  
CONCLUSIONS AND DISCUSSIONS 
  The study asks the question of what are the determinants of firm’s ability 
to launch products in the biotechnology industry. Prior studies have examined 
firm and inter-firm level causal factors to understand the determinants of a firm 
product performance. However, no studies to date have examined their 
interactive influences. Three contributions are made with this study. First, a 
theoretical and empirical framework is developed and tested that integrates firm 
level construct of absorptive capacity with the construct of strategic alliances. Our 
empirical results suggest that there are interactive influences between a firm 
absorptive capacity – in terms of its age and diversity of prior experiences- on its 
ability to absorb information and resources of its network partners. This 
interaction has positive influences on a firm’s product performance. To date, no 
studies have examined these firm and inter-firm level interactions. Second, our 
results also observe that such gains from absorptive capacity exhibit diminishing 
effects. This appears to be supported in the age and diversity measures of 
absorptive capacity. Hence, as there are diminishing effects from strategic 
alliance relationships, our results also suggest there may also be diminishing 
effects from a firm’s absorptive capacity. Third, various researchers have 
identified research and development and marketing alliance activities mutually 
complement the commercialization of biotechnology products (Teece, 2000). Our 
results suggest this is not the case and in particular, marketing and commercially 
related alliances appear to more greatly affect a firm’s product performance.   30 
In light of these contributions, there are, however, some limitations. First, 
panel data analysis is called for in future research. As the development of new 
products involves a temporal component, dynamic studies of product 
introductions would be fruitful area of investigation. Second, our proxy measures 
for absorptive capacity could be improved by developing measures used by 
Cohen and Levinthal (1990).  
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Table 1: Distribution of Biotechnology companies by product / service type marketed 
Type  Occurrence  Probability 
Agricultural  22  0.0394  3.94% 
Agricultural & Biotechnology  11  0.0197  1.97% 
Agricultural & Pharmaceutical  49  0.0877  8.77% 
Biotechnological  149  0.2665  26.65% 
Pharmaceutical  263  0.4705  47.05% 
Pharmaceutical & 
Biotechnological 
65  0.1163  11.63% 
TOTAL  559  1.0000  100.00%   36 
Table 2: Descriptive Statistics 
.   37 
Table 3: Correlation Matrix of Model Variables (N=241) 
   38 
Table 4: WLS Estimations 
 
* = p<1%, ** = p<5%, *** = p < 10% 